BTK and B-cell chronic lymphocytic leukemia: PI3K inhibitors, such as idelalisib, duvelisib, or umbralisib, have also demonstrated therapeutic activity in CLL patients, previously treated with BTK inhibitors, who developed progression on treatment [105].